Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus long antiplatelet therapy after TAVI
2023-508208-40-00Phase 3Authorised
- Sponsor
- CHU Caen Normandie
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Cartia and lysine acetylsalicylate in aortic stenosis (AS) and cardiac morbidity (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: Net clinical benefit at 12 months. Planned start Mar 2024; status: authorised.
02
Drugs
Cartialysine acetylsalicylate
03
Conditions
aortic stenosis (AS)cardiac morbidity
Beyond the preview
Go deeper on 2023-508208-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508208-40-00.